Appendix A. Progression-Free Survival: Additional Common Endpoints for the Study of Oncology Drugs

Disease-free survival (DFS): The time from random assignment to cancer recurrence or death from any cause.

Relapse-free survival (RFS): The time from treatment of disease to any event, irrespective of cause, except for any second primary cancers

Time to progression (TTP): The time from random assignment to disease progression. TTP does not include deaths, and these events are censored, either at the time of death or at an earlier visit.

Objective response rate (ORR): The proportion of subjects with a predefined amount of reduction in tumor burden as assessed on the basis of specific criteria such as the Response Evaluation Criteria in Solid Tumors (RECIST). Generally, ORR has been defined as the sum of partial responses plus complete responses (divided by total patients) and is considered a direct measure of drug antitumor activity.

Appendix B. Progression-Free Survival: Search Strategy

MEDLINE® (via PubMed) 1/10/12

Key Question 1:

"Disease-Free Survival"[Mesh] OR "progression free survival" OR "progression-free survival" OR "time to progression"
AND
(("Quality of Life"[Mesh]) OR ("Depression"[Mesh] OR "Depressive Disorder"[Mesh])) OR "Anxiety"[Mesh] OR “clinical benefit” OR “clinical benefits” OR “quality of life” OR “patient-reported outcomes” OR depression OR anxiety OR “psychological”
AND
"Neoplasms"[Mesh] OR cancer OR neoplasms OR carcinoma
AND
("progression-free" OR "progression free") Field: Title/Abstract
AND
Limits: Humans, English, Publication Date from 1999 to 2012
We made 2 sets – one with publication types letter, editorial, comment, OR review – the second was the rest of the articles in the set.

Key Question 2 includes the above search AND

Additional drug specific searches -
("bevacizumab" [Supplementary Concept] OR Bevacizumab OR avastin) AND ("Breast Neoplasms"[Mesh] OR (breast AND (cancer OR cancers OR neoplasms OR carcinoma*)) AND ("progression-free survival" OR "time to progression")

("ixabepilone" [Supplementary Concept] OR ixabepilone OR ixempra) AND ("Breast Neoplasms"[Mesh] OR (breast AND (cancer OR cancers OR neoplasms OR carcinoma*)) AND ("progression-free survival" OR "time to progression")

("lapatinib" [Supplementary Concept] OR lapatinib OR Tykerb) AND ("Breast Neoplasms"[Mesh] OR (breast AND (cancer OR cancers OR neoplasms OR carcinoma*)) AND ("progression-free survival" OR "time to progression")

("bevacizumab" [Supplementary Concept] OR Bevacizumab OR avastin) AND ("Colorectal Neoplasms"[Mesh] OR ((colon OR colorectal) AND (cancer OR cancers OR neoplasms OR carcinoma*))) AND ("progression-free survival" OR "time to progression")

("panitumumab" [Supplementary Concept] OR panitumumab OR vectibix) AND ("Colorectal Neoplasms"[Mesh] OR ((colon OR colorectal) AND (cancer OR cancers OR neoplasms OR carcinoma*))) AND ("progression-free survival" OR "time to progression")

("Doxorubicin"[Mesh] OR doxorubicin OR doxil) AND ("Ovarian Neoplasms"[Mesh] OR ((ovary OR ovarian) AND (cancer OR cancers OR neoplasms OR carcinoma*))) AND ("progression-free survival" OR "time to progression")

("gemcitabine" [Supplementary Concept] OR gemcitabine OR gemzar) AND ("Ovarian Neoplasms"[Mesh] OR ((ovary OR ovarian) AND (cancer OR cancers OR neoplasms OR carcinoma*))) AND ("progression-free survival" OR "time to progression")

("trabectedin" [Supplementary Concept] OR trabectedin OR yondelis) AND ("Ovarian Neoplasms"[Mesh] OR ((ovary OR ovarian) AND (cancer OR cancers OR neoplasms OR carcinoma*))) AND ("progression-free survival" OR "time to progression")

("sorafenib" [Supplementary Concept] OR sorafenib OR nexavar) AND ("Carcinoma, Renal Cell"[Mesh] OR "renal cell carcinoma") AND ("progression-free survival" OR "time to progression")

("pazopanib" [Supplementary Concept] OR pazopanib OR votrient) AND ("Carcinoma, Renal Cell"[Mesh] OR "renal cell carcinoma") AND ("progression-free survival" OR "time to progression")

("sunitinib" [Supplementary Concept] OR sunitinib OR sutent) AND ("Carcinoma, Renal Cell"[Mesh] OR "renal cell carcinoma") AND ("progression-free survival" OR "time to progression")

("erlotinib" [Supplementary Concept] OR erlotinib OR tarceva) AND ("Carcinoma, Non-Small-Cell Lung"[Mesh] OR ("non-small cell lung" AND (cancer OR cancers OR neoplasms OR carcinoma))) AND ("progression-free survival" OR "time to progression")

("docetaxel"[Mesh] OR doxetaxel OR taxotere) AND ("Head and Neck Neoplasms"[Mesh] OR (("head and neck") AND (cancer OR cancers OR carcinoma* OR neoplasms))) AND ("progression-free survival" OR "time to progression")

The EMBASE search was
'progression-free survival'/exp OR 'time to progression' in abstract or title
AND
'clinical benefit' OR 'clinical benefits' OR 'quality of life'/exp OR 'patient-reported outcomes' OR 'depression'/exp OR 'anxiety'/exp OR 'psychological'
AND
'cancer'/exp OR 'neoplasms'/exp OR 'carcinoma'/exp
AND
Human/English/1999-2012
NOT MEDLINE

MEDLINE 12/26/2011 = 293
For KQ1: ‘progression-free survival’/OR ‘PFS’
AND

‘clinical benefit’ OR ‘quality of life’ OR ‘patient-reported outcomes’ OR ‘depression’ OR ‘anxiety’ OR ‘psychological’
AND ‘cancer’
For KQ2: above AND each of the convenience drugs added individually
Limited to human/English/post 1999 (KQ1) or 2004 (KQ2)
above search limited to ‘randomized’ = 82

Sets – N=1505
From Medline = 82
KQ1_EMBASE = 426
KQ1_PubMed_EditComm=232 (these are the editorials, comments, letters and reviews from PubMed)
KQ1_PubMed_nonindexed=105 (these are the PubMed nonindexed that search obtained but that fell out when the English, Human and 1999-2012 limits were added)
KQ1_PubMed=655 (these are the PubMed results for the search strategy that we discussed minus the editorials, comments, letters and reviews above)
KQ2_PubMed=5 (these are the drug specific search results that were not already in the database – there were no drug specific search unique records in EMBASE).

Appendix C. Progression-Free Survival: List of Target Drugs

Oncology drugs for advanced solid epithelial cancers approved by regulatory authorities using PFS as the primary endpoint (2005 to 2010)

Targeted Cancer	Drug	Approved (jurisdictions)
Breast cancer – advanced	Avastin (bevacizumab)	US, Europe, Canada
Breast cancer – advanced	Ixempra (Ixabepilone)	US, Canada
Breast cancer— advanced	Tykerb (Lapatinib ditosylalte)	US, Europe, Canada
Colorectal cancer – advanced	Avastin (bevacizumab)	US, Europe, Canada
Colorectal Cancer – advanced	Vectibix (panitumumab)	US, Europe, Canada
Ovarian cancer— advanced	Doxil (Doxorubicin)	Europe, Canada
Ovarian cancer— advanced	Gemzar (gemcitabine)	US, Europe, Canada
Ovarian Cancer – advanced	Yondelis (trabectedin)	Europe, Canada
Renal Cell Cancer – advanced	Nexavar (sorafenib)	US, Europe, Canada
Renal Cell Cancer – advanced	Votrient (pazopanib)	US, Europe, Canada
Renal Cell Cancer – advanced	Sutent (sunitinib)	US, Europe, Canada
NSCLC - advanced	Tarceva (erlotinib)	US, Europe, Canada
Squamous Cell Cancer of Head and Neck - advanced	Taxotere (docetaxel)	US, Europe, Canada

Appendix D. Progression-Free Survival: Screening Questions

Title/Abstract Screening Questions

1.**Is this article published in English?**

- Yes
- No-EXCLUDE

2.**Is this a human study?**

- Yes
- No-EXCLUDE

3.**Is PFS an outcome measure?**

- Yes
- No-EXCLUDE

4. **Is this study**
A) a phase III (RCT) trial *AND*
B) does it address one of the combinations below:

Ixabepilone (Ixempra) - Breast cancer
Bevacizumab (Avastin) – breast cancer and colorectal cancer
lapatinib (Tykerb) - Breast cancer
panitumumab (Vectibix) - Colorectal cancer
doxorubicin (Doxil) - Ovarian cancer
gemcitabine (Gemzar) - Ovarian cancer
trabectedin (Yondelis) - Ovarian cancer
sorafenib (Nexavar) - RCC
pazopanib (Votrient) - RCC
sunitinib (Sutent) - RCC
erlotinib (Tarceva) - NSCLC
docetaxel (Taxotere) - Squamous cell ca of head and neck

- Yes BOTH A and B---KQ2
- No

5. Is there a PRO/QoL outcome? (This include outcomes that address psychological state, mood, depression, anxiety, hope)

- Yes
- No-EXCLUDE

6. **Do the authors of the article appear to be trying to establish a direct link between PFS and a PRO or Qol measure?**

- Yes or Uncertain---KQ1
- No-EXCLUDE

Full-Text Screening Questions

Click if applies:

- EXCLUDE - ABSTRACT ONLY, FULL-TEXT NOT AVAILABLE
- EXCLUDE – REVIEW
- EXCLUDE - CONFERENCE PRESENTATION

1. Does this study utilize one or more validated PRO/QoL tools to measure the PRO/QoL outcome(s) reported?

- Yes
- No-EXCLUDE

2. Does this article address one of the combinations below?:

Ixabepilone (Ixempra) - Breast cancer
Bevacizumab (Avastin) – breast cancer and colorectal cancer
lapatinib (Tykerb) - Breast cancer
panitumumab (Vectibix) - Colorectal cancer
doxorubicin (Doxil) - Ovarian cancer
gemcitabine (Gemzar) - Ovarian cancer
trabectedin (Yondelis) - Ovarian cancer
sorafenib (Nexavar) - RCC
pazopanib (Votrient) - RCC
sunitinib (Sutent) - RCC
erlotinib (Tarceva) - NSCLC
docetaxel (Taxotere) - Squamous cell ca of head and neck

- Yes-INCLUDE KQ2
- No

3. Does this study report a direct association between PFS and a PRO/QoL outcome? This study can be prospective or retrospective, observational and/or survey based.

- Yes-Include KQ1
- No-EXCLUDE

Appendix E. Progression-Free Survival: Abstraction Form Items

Study Characteristics

Refid
Author, Year
Key Question
Abstractor
Cancer type
Cancer Stage
Exp Drug v Control
Study Design
N Exp/Control
Age, Mean (SD); Median (range)

Treatment Efficacy and Safety

Primary Endpoint (Defined)
PFS, Experimental v Control, HR (95% CI)
OS, Experimental v Control, HR (95% CI)
ORR, Experimental v Control, % (95% CI)
Total Grade 3/4 AEs -- N (%) of pts on Experimental tx
Total Grade 3/4 AEs-- N (%) of pts in Control

QoL Description and PFS-QoL Association

QoL Tool Used
Threshold used for significant changes
Information on how the QoL was administered
Testing intervals for QoL, discontinuation criteria
QoL Timing for Drug treatment
QoL test (last administration) drop-out -- Experimental (N and % of total tx)
QoL test (last administration) drop-out -- Control (N and % of total tx)
Primary reasons for drop-out
Was Missing Data statistically addressed
PFS-QoL association descriptive results
PFS-QoL statistical method used

Appendix F. Progression-Free Survival: Relevance of Quality Assessment Items

Quality Criteria	Important to Drug Treatment Trials	Important in Studies Relating PFS to QoL	Unique to Trials Comparing PFS and QoL
Selection bias			
Subjects in different groups recruited from same population	X	X	
Subjects in different groups recruited over same time period	X	X	
Inclusion/exclusion criteria clearly stated	X	X	
Randomization used	X		
Comparable baseline characteristics between groups	X		
Apart from treatment under investigation, groups treated equally	X		
Similarity between groups in potentially important confounders (e.g., those with and without PFS) or adequate adjustment for confounding			X
Patients are not censored at progression			X
Performance bias			
PFS assessed in valid and reliable manner (central radiology review, RECIST criteria used, inter- and intra-observer variability reported)	X	X	
Subjects and investigators blind to treatment group	X	X	
Subjects awareness of PFS status is described			X
Attrition bias			
Missing data addressed through description and analysis	X	X	
Results unlikely to be affected by losses to follow-up	X	X	
Missing data likely to be at random	X	X	
Detection bias			
Outcome (progression) assessors blind to treatment group	X	X	
PFS and other endpoints defined	X	X	
QOL administration process was described	X	X	
A priori hypothesis regarding the relationship between PFS and QOL			X

APPENDIX G. Progression-Free Survival: Full-Text Screening, Articles Excluded, by Reason

Level 2, Form Full-Text Screening, -> EXCLUDE - ABSTRACT ONLY, FULL-TEXT NOT AVAILABLE...

Refid: 103, Estimating quality of life in advanced melanoma; A comparison of standard gamble, SF-36 mapped, and eortc QLQ-c30 mapped utilities
A. J. Batty, D. Fisher, B. Winn, Q. Wang, K. Tolley and D. Rowen
Level: 2, State: Excluded

Refid: 162, Patient preferences for non-small cell lung cancer (NSCLC) treatments
J. F. Bridges, A. Mohamed, H. W. Finnern, A. Woehl and A. B. Hauber
Level: 2, State: Excluded

Refid: 202, Time to deterioration (TTD) in patient-reported outcomes in phase 3 axis trial of axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)
D. Cella, B. Escudier, B. Rini, C. Chen, H. Bhattacharyya, J. Tarazi, B. Rosbrook, S. Kim and R. Motzer
Level: 2, State: Excluded

Refid: 232, Health-related quality of life (HRQOL) in 1st line non-squamous non-small cell lung cancer (NSCLC) patients in a real life setting: Bevacizumab-based versus non-bevacizumab based therapy in a european pilot study
C. Chouaid, H. G. Bischoff, A. Vergnenegre, D. F. Heigener, G. Taylor-Stokes, A. Roughley and S. Walzer
Level: 2, State: Excluded

Refid: 310, Asthenia and fatigue as potential biomarkers of sunitinib efficacy in metastatic renal cell carcinoma
M. P. Davis, R. A. Figlin, T. E. Hutson, D. Goldstein, S. Li, J. Perkins and R. J. Motzer
Level: 2, State: Excluded

Refid: 326, Patient preference-based utility weights from the functional assessment of cancer therapy-general (FACT-G) in women with hormone receptor positive metastatic breast cancer receiving letrozole plus lapatinib or letrozole alone
T. E. Delea, O. Sofrygin and M. Amonkar
Level: 2, State: Excluded

Refid: 396, Unresectable colorectal liver metastases treated by intraoperative radiofrequency ablation with or without resection: the ARF2003 study
S. Evrard, M. Rivoire, J. P. Arnaud, E. Lermite, C. Bellera, S. Mathoulin-Pelissier, M. Fonck, R. Brunet, Y. Becouarn and C. Lalet
Level: 2, State: Excluded

Refid: 496, Analysis of toxicity profile, Dose reduction and efficacy of sunitinib in metastatic renal cancer
C. Gonzalez-Perez, B. I. Pajares-Hachero, B. Muros-de Fuentes, J. Gonzalez-Contreras, A. I. Gomez-Sanchez and B. Solano-Hernandez
Level: 2, State: Excluded

Refid: 563, How much do patients with renal cell carcinoma (RCC) value progression free survival in medical decision making?-results from a benefit-risk conjoint study
A. B. Hauber, A. F. Mohamed, F. R. Johnson and M. P. Neary
Level: 2, State: Excluded

Refid: 679, Erlotinib maintenance therapy for non-small cell lung cancer preserves quality of life
E. Juhasz, J. H. Kim, L. Stelmakh, S. Cicenas and G. Klingelschmitt
Level: 2, State: Excluded

Refid: 772, Efficacy of Biological Agents (BA) in metastatic Triple Negative Breast Cancer (TNBC): A systematic review
N. M. La Verde, A. Bramati, P. Sburlati, E. Galfrascoli, A. Moretti, A. Bianchi, S. Girelli, S. Piva, M. C. Garassino and G. Farina
Level: 2, State: Excluded

Refid: 807, Sofrafenib versus sunitinib in metastatic renal cell carcinoma: Indirect comparison analysis
H. W. Leung and A. L. Chan
Level: 2, State: Excluded

Refid: 1007, Ariadna study - Evaluation of symptoms on daily life and health-related quality of life (HRQOL) of patients with advanced non-small cell lung cancer (NSCLC)
J. Oramas, M. Cobo, A. Paredes, E. Arriola, M. Sala, A. Artal, R. Girones, M. J. Martinez, S. Figueroa and M. Domine
Level: 2, State: Excluded

Refid: 1144, An interim analysis of health-related quality of life (HRQOL) in patients with non-squamous non-small-cell lung cancer (NSNSCLC) receiving bevacizumab vs bevacizumab + pemetrexed for maintenance therapy in avaperl 1
A. Rittmeyer, C. Chouaid, J. H. Kim, M. J. Ahn, V. Gorbunova, A. Scherpereel, J. Oramas, S. Walzer and F. Barlesi
Level: 2, State: Excluded

Refid: 1350, Utility elicitation study in the UK general public for late stage chronic lymphocytic leukemia
K. Tolley, C. Goad, Y. Yi, P. A. Maroudas and G. Thompson
Level: 2, State: Excluded

Refid: 1370, Bevacizumab in combination with chemotherapy for the first-line treatment of metastatic colorectal cancer

R. Ubago, M. A. Castillo, S. Flores and C. Beltran
Level: 2, State: Excluded

Refid: 1434, A Q-twist analysis comparing panitumumab plus best supportive care (BSC) with bsc alone in patients with wild-type kras metastatic colorectal cancer
J. Wang, Z. Zhao, B. Sherrill, M. Peeters, J. Wiezorek and B. Barber
Level: 2, State: Excluded

Refid: 1469, Tumour response, skin rash and health-related quality of life (HRQOL) - Post-HOC data from the IPASS study
Y. Wu, M. Fukuoka, T. S. K. Mok, N. Saijo, S. Thongprasert, J. C. H. Yang, D. T. Chu, J. J. Yang and Y. Rukazenkov
Level: 2, State: Excluded

Level 2, Form Full-Text Screening, -> EXCLUDE - REVIEW

Refid: 110, Sunitinib in Advanced Renal Cell Carcinoma: Clinical Evidence
J. Bellmunt
Level: 2, State: Excluded

Refid: 231, Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer
G. Chornokur, K. Dalton, M. E. Borysova and N. B. Kumar
Level: 2, State: Excluded

Refid: 275, Targeted therapy for advanced renal cell carcinoma
C. Coppin, L. Le, F. Porzsolt and T. Wilt
Level: 2, State: Excluded

Refid: 308, Temozolomide: A review of its use in the treatment of malignant gliomas, malignant melanoma and other advanced cancers
M. J. M. Darkes, G. L. Plosker and B. Jarvis
Level: 2, State: Excluded

Refid: 347, Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: A NICE single technology appraisal
R. Dickson, A. Bagust, A. Boland, M. Blundell, H. Davis, Y. Dundar, J. Hockenhull, C. Martin Saborido, J. Oyee and V. S. Ramani
Level: 2, State: Excluded

Refid: 984, The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use
M. Nieto, J. Borregaard, J. Ersboll, G. J. A. Ten Bosch, B. Van Zwieten-Boot, E. Abadie, J. H. M. Schellens and F. Pignatti
Level: 2, State: Excluded

Refid: 1043, Panitumumab in Combination With Cytotoxic Chemotherapy for the Treatment of Metastatic Colorectal Carcinoma
M. Peeters, A. Cohn, C. H. Kohne and J. Y. Douillard
Level: 2, State: Excluded

Refid: 1145, Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial
F. Rivera, A. Garcia-Castano, N. Vega, M. E. Vega-Villegas and L. Gutierrez-Sanz
Level: 2, State: Excluded

Refid: 1437, Panitumumab: in metastatic colorectal cancer with wild-type KRAS
J. Weber and P. L. McCormack
Level: 2, State: Excluded

Refid: 1449, Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer
S. Whyte, A. Pandor, M. Stevenson and A. Rees
Level: 2, State: Excluded

Level 2, Form Full-Text Screening, -> EXCLUDE - CONFERENCE PRESENTATION

Refid: 1208, Do hope, optimism and other psychological factors predict survival in patients with metastatic colorectal cancer?
P. Schofield, M. Stockler, D. Zannino, N. Wong, D. Ransom, E. Moylan, J. Simes, T. Price, N. Tebbutt and M. Jefford
Level: 2, State: Excluded

Level 2, Form Full-Text Screening, Does this study utilize one or more validated PRO/QoL tools to measure the PRO/QoL outcome(s) reported?... -> No-EXCLUDE

Refid: 24, Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200)
D. S. Alberts, P. Y. Liu, S. P. Wilczynski, M. C. Clouser, A. M. Lopez, D. P. Michelin, V. J. Lanzotti and M. Markman
Level: 2, State: Excluded

Refid: 35, Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer
E. Amir, A. Ocana, B. Seruga, O. Freedman and M. Clemons
Level: 2, State: Excluded

Refid: 131, Randomized study of Lapatinib alone or in combination with trastuzumab in women

with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
K. L. Blackwell, H. J. Burstein, A. M. Storniolo, H. Rugo, G. Sledge, M. Koehler, C. Ellis, M. Casey, S. Vukelja, J. Bischoff, J. Baselga and J. O'Shaughnessy
Level: 2, State: Excluded

Refid: 252, Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis
B. F. Cole, M. J. Glantz, K. A. Jaeckle, M. C. Chamberlain and J. I. Mackowiak
Level: 2, State: Excluded

Refid: 384, Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma
A. A. Elfiky, D. C. Cho, D. F. McDermott, J. E. Rosenberg, B. Fortner, L. Antras, K. Chen, M. Sheng Duh, S. S. Jayawant, W. K. Oh, M. B. Atkins and T. K. Choueiri
Level: 2, State: Excluded

Refid: 453, Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer
J. A. Garcia-Saenz, M. Martin, A. Calles, C. Bueno, L. Rodriguez, J. Bobokova, A. Custodio, A. Casado and E. Diaz-Rubio
Level: 2, State: Excluded

Refid: 484, U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens
R. M. Giusti, K. Shastri, A. M. Pilaro, C. Fuchs, R. Cordoba-Rodriguez, K. Koti, M. Rothmann, A. Y. Men, H. Zhao, M. Hughes, P. Keegan, K. D. Weiss and R. Pazdur
Level: 2, State: Excluded

Refid: 485, FDA drug approval summary: panitumumab (Vectibix)
R. M. Giusti, K. A. Shastri, M. H. Cohen, P. Keegan and R. Pazdur
Level: 2, State: Excluded

Refid: 529, Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
Z. Z. Guan, J. M. Xu, R. C. Luo, F. Y. Feng, L. W. Wang, L. Shen, S. Y. Yu, Y. Ba, J. Liang, D. Wang, S. K. Qin, J. J. Wang, J. He, C. Qi and R. H. Xu
Level: 2, State: Excluded

Refid: 571, A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
J. R. Hecht, E. Mitchell, T. Chidiac, C. Scroggin, C. Hagenstad, D. Spigel, J. Marshall, A. Cohn, D. McCollum, P. Stella, R. Deeter, S. Shahin and R. G. Amado
Level: 2, State: Excluded

Refid: 575, Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup

analyses from the TRUST study
D. F. Heigener, Y. L. Wu, N. van Zandwijk, P. Mali, K. Horwood and M. Reck
Level: 2, State: Excluded

Refid: 629, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross and F. Kabbinavar
Level: 2, State: Excluded

Refid: 630, The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer
H. I. Hurwitz, J. Yi, W. Ince, W. F. Novotny and O. Rosen
Level: 2, State: Excluded

Refid: 637, Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials
E. M. Ibrahim and K. M. Abouelkhair
Level: 2, State: Excluded

Refid: 643, Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer
W. Irish, B. Sherrill, B. Cole, C. Gard, G. A. Glendenning and H. Mouridsen
Level: 2, State: Excluded

Refid: 666, Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen
J. R. Johnson, M. Cohen, R. Sridhara, Y. F. Chen, G. M. Williams, J. Duan, J. Gobburu, B. Booth, K. Benson, J. Leighton, L. S. Hsieh, N. Chidambaram, P. Zimmerman and R. Pazdur
Level: 2, State: Excluded

Refid: 667, Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
S. Johnston, J. Pippen, Jr., X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H. L. Gomez, G. Romieu, A. Manikhas, M. J. Kennedy, M. F. Press, J. Maltzman, A. Florance, L. O'Rourke, C. Oliva, S. Stein and M. Pegram
Level: 2, State: Excluded

Refid: 680, Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials
F. F. Kabbinavar, H. I. Hurwitz, J. Yi, S. Sarkar and O. Rosen
Level: 2, State: Excluded

Refid: 808, Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-

analysis
H. W. C. Leung and A. L. F. Chan
Level: 2, State: Excluded

Refid: 823, VEGF pathway-targeted therapy for advanced renal cell carcinoma: A meta-analysis of randomized controlled trials
F. Liu, X. Chen, E. Peng, W. Guan, Y. Li, Z. Hu, Z. Ye and Q. Zhuang
Level: 2, State: Excluded

Refid: 870, Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
M. Markman, J. Moon, S. Wilczynski, A. M. Lopez, K. M. Rowland Jr, D. P. Michelin, V. J. Lanzotti, G. L. Anderson and D. S. Alberts
Level: 2, State: Excluded

Refid: 883, SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer
E. L. Mayer, S. Dhakil, T. Patel, S. Sundaram, C. Fabian, M. Kozloff, R. Qamar, F. Volterra, H. Parmar, M. Samant and H. J. Burstein
Level: 2, State: Excluded

Refid: 914, Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
D. W. Miles, A. Chan, L. Y. Dirix, J. Cortes, X. Pivot, P. Tomczak, T. Delozier, J. H. Sohn, L. Provencher, F. Puglisi, N. Harbeck, G. G. Steger, A. Schneeweiss, A. M. Wardley, A. Chlistalla and G. Romieu
Level: 2, State: Excluded

Refid: 933, Early adjuvant radiotherapy toward long-term survival and better quality of life for craniopharyngiomas--a study in single institute
S. H. Moon, I. H. Kim, S. W. Park, I. Kim, S. Hong, C. I. Park, K. C. Wang and B. K. Cho
Level: 2, State: Excluded

Refid: 971, Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET
S. Negrier, E. Jager, C. Porta, D. McDermott, M. Moore, J. Bellmunt, S. Anderson, F. Cihon, J. Lewis, B. Escudier and R. Bukowski
Level: 2, State: Excluded

Refid: 981, Management of spinal metastases from renal cell carcinoma using stereotactic body radiotherapy
Q. N. Nguyen, A. S. Shiu, L. D. Rhines, H. Wang, P. K. Allen, X. S. Wang and E. L. Chang
Level: 2, State: Excluded

Refid: 1055, Erlotinib as maintenance therapy in patients with advanced non-small cell lung

cancer: A pooled analysis of three randomized trials
F. Petrelli, K. Borgonovo, M. Cabiddu and S. Barni
Level: 2, State: Excluded

Refid: 1068, Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers
M. S. Pino, M. Milella, A. Gelibter, I. Sperduti, S. De Marco, C. Nuzzo, E. Bria, L. Carpanese, E. M. Ruggeri, P. Carlini and F. Cognetti
Level: 2, State: Excluded

Refid: 1089, Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
E. Pujade-Lauraine, U. Wagner, E. Aavall-Lundqvist, V. Gebski, M. Heywood, P. A. Vasey, B. Volgger, I. Vergote, S. Pignata, A. Ferrero, J. Sehouli, A. Lortholary, G. Kristensen, C. Jackisch, F. Joly, C. Brown, N. Le Fur and A. du Bois
Level: 2, State: Excluded

Refid: 1142, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
B. I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T. E. Hutson, M. D. Michaelson, V. A. Gorbunova, M. E. Gore, I. G. Rusakov, S. Negrier, Y. C. Ou, D. Castellano, H. Y. Lim, H. Uemura, J. Tarazi, D. Cella, C. Chen, B. Rosbrook, S. Kim and R. J. Motzer
Level: 2, State: Excluded

Refid: 1151, RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
N. J. Robert, V. Dieras, J. Glaspy, A. M. Brufsky, I. Bondarenko, O. N. Lipatov, E. A. Perez, D. A. Yardley, S. Y. T. Chan, X. Zhou, S.-C. Phan and J. O'Shaughnessy
Level: 2, State: Excluded

Refid: 1184, Balancing risk and benefit for first-line treatment of metastatic colorectal cancer: a graphic communication tool for patients and physicians
M. S. Sanatani and M. D. Vincent
Level: 2, State: Excluded

Refid: 1201, Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial
W. Scheithauer, B. Schull, H. Ulrich-Pur, K. Schmid, M. Raderer, K. Haider, W. Kwasny, D. Depisch, B. Schneeweiss, F. Lang and G. V. Kornek
Level: 2, State: Excluded

Refid: 1217, Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.[Erratum appears in Oncologist. 2010;15(3):327 Note: Schwarzberg, Lee S [corrected to Schwartzberg, Lee S]]
L. S. Schwartzberg, S. X. Franco, A. Florance, L. O'Rourke, J. Maltzman and S. Johnston

Level: 2, State: Excluded

Refid: 1241, Erlotinib in previously treated non-small-cell lung cancer
F. A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E. H. Tan, V. Hirsh, S. Thongprasert, D. Campos, S. Maoleekoonpiroj, M. Smylie, R. Martins, M. van Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara and L. Seymour
Level: 2, State: Excluded

Refid: 1322, A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma
K. Taoka, Y. Okoshi, N. Sakamoto, S. Takano, A. Matsumura, Y. Hasegawa and S. Chiba
Level: 2, State: Excluded

Refid: 1360, 1. Sorafenib in advanced clear-cell renal-cell carcinoma. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group, Department of Medicine, Institut Gustave Roussy, Villejuif, France
D. L. Trump
Level: 2, State: Excluded

Refid: 1378, Magnitude of benefit of the addition of bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials
V. Vaccaro, F. Cuppone, F. Loupakis, M. Milella, P. Carlini, C. Nistico, A. Falcone, E. Terzoli, F. Cognetti and E. Bria
Level: 2, State: Excluded

Refid: 1424, Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies
B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark and P. J. Cagnoni
Level: 2, State: Excluded

Refid: 1433, A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
J. Wang, Z. Zhao, B. Barber, B. Sherrill, M. Peeters and J. Wiezorek
Level: 2, State: Excluded

Refid: 1488, Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review
A. Y. Yip, L. A. Tse, E. Y. Ong and L. W. Chow
Level: 2, State: Excluded

Refid: 1507, Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
E. S. Thomas, H. L. Gomez, R. K. Li, H. C. Chung, L. E. Fein, V. F. Chan, J. Jassem, X. B.

Pivot, J. V. Klimovsky, F. H. de Mendoza, B. Xu, M. Campone, G. L. Lerzo, R. A. Peck, P. Mukhopadhyay, L. T. Vahdat and H. H. Roche
Level: 2, State: Excluded

Refid: 1509, beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial
K. J. Cullen, L. Schumaker, N. Nikitakis, O. Goloubeva, M. Tan, N. J. Sarlis, R. I. Haddad and M. R. Posner
Level: 2, State: Excluded

Refid: 1514, Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial
J. H. Lorch, O. Goloubeva, R. I. Haddad, K. Cullen, N. Sarlis, R. Tishler, M. Tan, J. Fasciano, D. E. Sammartino and M. R. Posner
Level: 2, State: Excluded

Refid: 1516, Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation
M. R. Posner, C. M. Norris, L. J. Wirth, D. M. Shin, K. J. Cullen, E. W. Winquist, C. R. Blajman, E. A. Mickiewicz, G. P. Frenette, L. F. Plinar, R. B. Cohen, L. M. Steinbrenner, J. M. Freue, V. A. Gorbunova, S. A. Tjulandin, L. E. Raez, D. R. Adkins, R. B. Tishler, M. R. Roessner and R. I. Haddad
Level: 2, State: Excluded

Refid: 1518, Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
J. B. Vermorken, E. Remenar, C. van Herpen, T. Gorlia, R. Mesia, M. Degardin, J. S. Stewart, S. Jelic, J. Betka, J. H. Preiss, D. van den Weyngaert, A. Awada, D. Cupissol, H. R. Kienzer, A. Rey, I. Desaunois, J. Bernier and J. L. Lefebvre
Level: 2, State: Excluded

Level 2, Form Full-Text Screening, Does this study report a direct association between PFS and a PRO/QOL outcome? -> No-EXCLUDE

Refid: 73, Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial
H. J. Au, C. S. Karapetis, C. J. O'Callaghan, D. Tu, M. J. Moore, J. R. Zalcberg, H. Kennecke, J. D. Shapiro, S. Koski, N. Pavlakis, D. Charpentier, D. Wyld, M. Jefford, G. J. Knight, N. M. Magoski, M. D. Brundage and D. J. Jonker
Level: 2, State: Excluded

Refid: 87, Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment

A. Bamias, G. Lainakis, E. Kastritis, N. Antoniou, G. Alivizatos, A. Koureas, M. Chrisofos, A. Skolarikos, E. Karayiotis and M. A. Dimopoulos
Level: 2, State: Excluded

Refid: 108, Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy
J. L. Beaumont, Z. Butt, J. Baladi, R. J. Motzer, T. Haas, N. Hollaender, A. Kay and D. Cella
Level: 2, State: Excluded

Refid: 114, Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
L. Bennett, Z. Zhao, B. Barber, X. Zhou, M. Peeters, J. Zhang, F. Xu, J. Wiezorek and J. Y. Douillard
Level: 2, State: Excluded

Refid: 152, Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
M. Brada, K. Hoang-Xuan, R. Rampling, P. Y. Dietrich, L. Y. Dirix, D. Macdonald, J. J. Heimans, B. A. Zonnenberg, J. M. Bravo-Marques, R. Henriksson, R. Stupp, N. Yue, J. Bruner, M. Dugan, S. Rao and S. Zaknoen
Level: 2, State: Excluded

Refid: 167, Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer
R. Bukowski, D. Cella, K. Gondek, B. Escudier and T. C. T. G. Sorafenib
Level: 2, State: Excluded

Refid: 189, The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer
M. S. Carey, M. Bacon, D. Tu, L. Butler, A. Bezjak and G. C. Stuart
Level: 2, State: Excluded

Refid: 200, Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
D. Cella, A. G. Bushmakin, J. C. Cappelleri, C. Charbonneau, M. D. Michaelson and R. J. Motzer
Level: 2, State: Excluded

Refid: 201, Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa
D. Cella, J. C. Cappelleri, A. Bushmakin, C. Charbonneau, J. Z. Li, S. T. Kim, I. Chen, M. D. Michaelson and R. J. Motzer
Level: 2, State: Excluded

Refid: 204, Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib

or interferon alfa: results from a phase III randomized trial
D. Cella, J. Z. Li, J. C. Cappelleri, A. Bushmakin, C. Charbonneau, S. T. Kim, I. Chen and R. J. Motzer
Level: 2, State: Excluded

Refid: 260, Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet
P. Comella, R. Casaretti, R. Manzo, C. Sandomenico, M. Licenziato, A. Avallone and L. Franco
Level: 2, State: Excluded

Refid: 285, Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
B. Coudert, T. Ciuleanu, K. Park, Y. L. Wu, G. Giaccone, W. Brugger, P. Gopalakrishna and F. Cappuzzo
Level: 2, State: Excluded

Refid: 313, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Le Bail, C. Louvet, D. Hendler, F. de Braud, C. Wilson, F. Morvan and A. Bonetti
Level: 2, State: Excluded

Refid: 315, Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer
F. de Marinis, J. R. Pereira, F. Fossella, M. C. Perry, M. Reck, M. Salzberg, J. Jassem, P. Peterson, A. M. Liepa, P. Moore and R. J. Gralla
Level: 2, State: Excluded

Refid: 365, Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
A. du Bois, J. Herrstedt, A. C. Hardy-Bessard, H. H. Muller, P. Harter, G. Kristensen, F. Joly, J. Huober, E. Avall-Lundqvist, B. Weber, C. Kurzeder, S. Jelic, E. Pujade-Lauraine, A. Burges, J. Pfisterer, M. Gropp, A. Staehle, P. Wimberger, C. Jackisch and J. Sehouli
Level: 2, State: Excluded

Refid: 412, Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma
D. A. Fennell, C. S. JP, J. Shamash, M. T. Sheaff, M. T. Evans, T. I. Goonewardene, M. L. Nystrom, N. H. Gower and R. M. Rudd
Level: 2, State: Excluded

Refid: 416, Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
P. M. Fidias, S. R. Dakhil, A. P. Lyss, D. M. Loesch, D. M. Waterhouse, J. L. Bromund, R.

Chen, M. Hristova-Kazmierski, J. Treat, C. K. Obasaju, M. Marciniak, J. Gill and J. H. Schiller
Level: 2, State: Excluded

Refid: 449, Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial
J. Gallego Perez-Larraya, F. Ducray, O. Chinot, I. Catry-Thomas, L. Taillandier, J. S. Guillamo, C. Campello, A. Monjour, S. Cartalat-Carel, M. Barrie, A. Huchet, P. Beauchesne, M. Matta, K. Mokhtari, M. L. Tanguy, J. Honnorat and J. Y. Delattre
Level: 2, State: Excluded

Refid: 660, Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF-C-HIT
A. D. Jensen, J. Krauss, K. Potthoff, A. Desta, G. Habl, A. Mavtratzas, C. Windemuth-Kiesselbach, J. Debus and M. W. Munter
Level: 2, State: Excluded

Refid: 682, Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer
F. F. Kabbinavar, J. F. Wallace, E. Holmgren, J. Yi, D. Cella, K. J. Yost and H. I. Hurwitz
Level: 2, State: Excluded

Refid: 915, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
K. Miller, M. Wang, J. Gralow, M. Dickler, M. Cobleigh, E. A. Perez, T. Shenkier, D. Cella and N. E. Davidson
Level: 2, State: Excluded

Refid: 916, Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
K. D. Miller, L. I. Chap, F. A. Holmes, M. A. Cobleigh, P. K. Marcom, L. Fehrenbacher, M. Dickler, B. A. Overmoyer, J. D. Reimann, A. P. Sing, V. Langmuir and H. S. Rugo
Level: 2, State: Excluded

Refid: 947, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. Negrier, C. Szczylik, S. T. Kim, I. Chen, P. W. Bycott, C. M. Baum and R. A. Figlin
Level: 2, State: Excluded

Refid: 957, Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
D. G. Mutch, M. Orlando, T. Goss, M. G. Teneriello, A. N. Gordon, S. D. McMeekin, Y. Wang, D. R. Scribner, Jr., M. Marciniack, R. W. Naumann and A. A. Secord
Level: 2, State: Excluded

Refid: 996, Health-related quality of life and colorectal cancer-specific symptoms in patients

with chemotherapy-refractory metastatic disease treated with panitumumab
D. Odom, B. Barber, L. Bennett, M. Peeters, Z. Zhao, J. Kaye, M. Wolf and J. Wiezorek
Level: 2, State: Excluded

Refid: 1044, Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy
M. Peeters, S. Siena, E. Van Cutsem, A. Sobrero, A. Hendlisz, S. Cascinu, H. Kalofonos, G. Devercelli, M. Wolf and R. G. Amado
Level: 2, State: Excluded

Refid: 1046, Experience of external beam radiotherapy given adjuvantly or at relapse following surgery for craniopharyngioma
L. S. Pemberton, M. Dougal, B. Magee and H. R. Gattamaneni
Level: 2, State: Excluded

Refid: 1060, Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, A. J. Lacave, U. Wagner, A. Stahle, G. Stuart, R. Kimmig, S. Olbricht, T. Le, J. Emerich, W. Kuhn, J. Bentley, C. Jackisch, H. J. Luck, J. Rochon, A. H. Zimmermann and E. Eisenhauer
Level: 2, State: Excluded

Refid: 1061, Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer
J. Pfisterer, I. Vergote, A. Du Bois and E. Eisenhauer
Level: 2, State: Excluded

Refid: 1066, Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial
S. Pignata, G. Scambia, G. Ferrandina, A. Savarese, R. Sorio, E. Breda, V. Gebbia, P. Musso, L. Frigerio, P. Del Medico, A. V. Lombardi, A. Febbraro, P. Scollo, A. Ferro, S. Tamberi, A. Brandes, A. Ravaioli, M. R. Valerio, E. Aitini, D. Natale, L. Scaltriti, S. Greggi, C. Pisano, D. Lorusso, V. Salutari, F. Legge, M. Di Maio, A. Morabito, C. Gallo and F. Perrone
Level: 2, State: Excluded

Refid: 1073, Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial
R. Pokrzywinski, A. A. Secord, L. J. Havrilesky, L. E. Puls, R. W. Holloway, G. S. Lewandowski, R. V. Higgins, L. R. Nycum, M. F. Kohler and D. A. Revicki
Level: 2, State: Excluded

Refid: 1129, Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
M. Reni, L. Pasetto, G. Aprile, S. Cordio, E. Bonetto, S. Dell'Oro, P. Passoni, L. Piemonti, C.

Fugazza, G. Luppi, C. Milandri, R. Nicoletti, A. Zerbi, G. Balzano, V. Di Carlo and A. A. Brandes
Level: 2, State: Excluded

Refid: 1198, Interferon-alpha as maintenance therapy in patients with multiple myeloma
C. G. Schaar, H. C. Kluin-Nelemans, C. Te Marvelde, S. le Cessie, W. P. Breed, W. E. Fibbe, W. A. van Deijk, M. M. Fickers, K. J. Roozendaal and P. W. Wijermans
Level: 2, State: Excluded

Refid: 1204, Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93)
J. C. Schink, E. Weller, L. S. Harris, D. Cella, J. Gerstner, C. Falkson and S. Wadler
Level: 2, State: Excluded

Refid: 1288, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
C. N. Sternberg, I. D. Davis, J. Mardiak, C. Szczylik, E. Lee, J. Wagstaff, C. H. Barrios, P. Salman, O. A. Gladkov, A. Kavina, J. J. Zarba, M. Chen, L. McCann, L. Pandite, D. F. Roychowdhury and R. E. Hawkins
Level: 2, State: Excluded

Refid: 1307, Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer
H. Svensson, T. Hatschek, H. Johansson, Z. Einbeigi and Y. Brandberg
Level: 2, State: Excluded

Refid: 1334, Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
N. C. Tebbutt, K. Wilson, V. J. Gebski, M. M. Cummins, D. Zannino, G. A. van Hazel, B. Robinson, A. Broad, V. Ganju, S. P. Ackland, G. Forgeson, D. Cunningham, M. P. Saunders, M. R. Stockler, Y. Chua, J. R. Zalcberg, R. J. Simes and T. J. Price
Level: 2, State: Excluded

Refid: 1340, High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients
E. Terzoli, C. Garufi, A. R. Zappala, B. Vanni, P. Pugliese, G. A. Cappellini, A. M. Aschelter, M. Perrone and D. Giannarelli
Level: 2, State: Excluded

Refid: 1349, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
J. Tol, M. Koopman, A. Cats, C. J. Rodenburg, G. J. M. Creemers, J. G. Schrama, F. L. G. Erdkamp, A. H. Vos, C. J. van Groeningen, H. A. M. Sinnige, D. J. Richel, E. E. Voest, J. R. Dijkstra, M. E. Vink-Borger, N. F. Antonini, L. Mol, J. H. J. M. van Krieken, O. Dalesio and C. J. A. Punt

Level: 2, State: Excluded

Refid: 1383, Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group
E. Van Cutsem and G. H. Blijham
Level: 2, State: Excluded

Refid: 1440, Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer
J. T. Wei, R. L. Dunn, H. M. Sandler, P. W. McLaughlin, J. E. Montie, M. S. Litwin, L. Nyquist and M. G. Sanda
Level: 2, State: Excluded

Refid: 1445, Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study
L. B. Wenzel, H. Q. Huang, D. K. Armstrong, J. L. Walker and D. Cella
Level: 2, State: Excluded

Refid: 1447, Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
P. Wheatley-Price, K. Ding, L. Seymour, G. M. Clark and F. A. Shepherd
Level: 2, State: Excluded

Refid: 1468, Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer
Y. Wu, M. M. Amonkar, B. H. Sherrill, J. O'Shaughnessy, C. Ellis, J. Baselga, K. L. Blackwell and H. J. Burstein
Level: 2, State: Excluded

Refid: 1495, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
W. K. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink, M. D. Prados, M. Brada, A. Spence, R. J. Hohl, W. Shapiro, M. Glantz, H. Greenberg, R. G. Selker, N. A. Vick, R. Rampling, H. Friedman, P. Phillips, J. Bruner, N. Yue, D. Osoba, S. Zaknoen and V. A. Levin
Level: 2, State: Excluded

Refid: 1496, Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group
W. K. Yung, M. D. Prados, R. Yaya-Tur, S. S. Rosenfeld, M. Brada, H. S. Friedman, R. Albright, J. Olson, S. M. Chang, A. M. O'Neill, A. H. Friedman, J. Bruner, N. Yue, M. Dugan, S. Zaknoen and V. A. Levin
Level: 2, State: Excluded

Refid: 1508, Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21
A. Bezjak, D. Tu, L. Seymour, G. Clark, A. Trajkovic, M. Zukin, J. Ayoub, S. Lago, R. de

Albuquerque Ribeiro, A. Gerogianni, A. Cyjon, J. Noble, F. Laberge, R. T. Chan, D. Fenton, J. von Pawel, M. Reck and F. A. Shepherd
Level: 2, State: Excluded